KalVista Pharmaceuticals, Inc.

KALV

US4834971032

Pharmaceuticals

Market Closed - Nasdaq Other stock markets 01:30:00 06/07/2024 am IST			5-day change	1st Jan Change
11.79 ^USD	+0.60%		+0.08%	-3.76%

01/07	KalVista Pharmaceuticals, Inc.(NasdaqGM:KALV) added to Russell 3000 Growth Index	CI
01/07	KalVista Pharmaceuticals, Inc.(NasdaqGM:KALV) dropped from Russell Microcap Value Index	CI

KalVista Pharmaceuticals, Inc.(NasdaqGM:KALV) added to Russell 3000E Growth Index

July 01, 2024

Latest news about KalVista Pharmaceuticals, Inc.

KalVista Pharmaceuticals, Inc.(NasdaqGM:KALV) added to Russell 3000 Growth Index	01/07	CI
KalVista Pharmaceuticals, Inc.(NasdaqGM:KALV) dropped from Russell Microcap Value Index	01/07	CI
KalVista Pharmaceuticals, Inc.(NasdaqGM:KALV) dropped from Russell 3000E Value Index	01/07	CI
KalVista Pharmaceuticals, Inc.(NasdaqGM:KALV) dropped from Russell 3000 Value Index	01/07	CI
KalVista Pharmaceuticals, Inc.(NasdaqGM:KALV) dropped from Russell 2500 Value Index	01/07	CI
KalVista Pharmaceuticals, Inc.(NasdaqGM:KALV) dropped from Russell Small Cap Comp Value Index	01/07	CI
KalVista Pharmaceuticals, Inc.(NasdaqGM:KALV) added to Russell Microcap Growth Index	01/07	CI
KalVista Pharmaceuticals, Inc.(NasdaqGM:KALV) dropped from Russell 2000 Value Index	01/07	CI
KalVista Pharmaceuticals, Inc.(NasdaqGM:KALV) added to Russell 3000E Growth Index	01/07	CI
KalVista Pharmaceuticals, Inc.(NasdaqGM:KALV) added to Russell 2000 Growth Index	01/07	CI
KalVista Pharmaceuticals, Inc.(NasdaqGM:KALV) added to Russell 2500 Growth Index	01/07	CI
KalVista Pharmaceuticals, Inc.(NasdaqGM:KALV) added to Russell Small Cap Comp Growth Index	01/07	CI
KalVista Starts Hereditary Angioedema Trial in Pediatric Patients	27/06	MT
KalVista Pharmaceuticals, Inc. Initiates KONFident-KID Trial for On-Demand Treatment of Hereditary Angioedema Attacks with Sebetralstat in Children Aged 2 to 11	27/06	CI
KalVista Pharmaceuticals Submits New Drug Application to FDA for Investigational Hereditary Angioedema Treatment	18/06	MT
KalVista Seeks FDA OK of Sebetralstat for Hereditary-Angioedema Attacks	18/06	DJ
KalVista Pharmaceuticals, Inc. Submits New Drug Application to FDA for Sebetralstat as First Oral On-Demand Treatment for Hereditary Angioedema	18/06	CI
KalVista Pharmaceuticals, Inc. Presents Data At Eastern Allergy Conference 2024 and the Japanese Dermatological Association 2024	06/06	CI
Kalvista Pharmaceuticals Presents Data on Persisting Unmet Needs in Hereditary Angioedema At the European Academy of Allergy and Clinical Immunology Congress 2024	03/06	CI
Sector Update: Health Care Stocks Higher Late Afternoon	01/06	MT
Sector Update: Health Care	01/06	MT
KalVista Prospective Treatment for Swelling Disorder Meets Objectives -- Shares Rise	31/05	MT
Kalvista Pharmaceuticals Announces New England Journal of Medicine Publishes Oral Sebetralstat Phase 3 Data Demonstrating Its Potential to Transform the Treatment Landscape for People with Hereditary Angioedema	31/05	CI
Kalvista Pharmaceuticals Insider Sold Shares Worth $258,337, According to a Recent SEC Filing	22/05	MT
Kalvista Pharmaceuticals, Inc. Appoints William C. Fairey to the Board of Directors	22/04	CI

Chart KalVista Pharmaceuticals, Inc.

Duration

Period

More charts

KalVista Pharmaceuticals, Inc. is a clinical-stage pharmaceutical company. The Company is focused on the discovery, development and commercialization of small molecule protease inhibitors for diseases with unmet need. The Company has developed a portfolio of small molecule plasma kallikrein inhibitors targeting the disease hereditary angioedema (HAE). The Company is developing sebetralstat as an oral on-demand therapy for HAE attacks and has achieved target enrollment for the phase 3 KONFIDENT clinical trial. The Company is also conducting preclinical development on oral Factor XIIa (Factor XIIa) inhibitor program, which is advancing to provide the next generation of HAE therapeutics. It is also focused on development of oral plasma kallikrein inhibitors for HAE and Factor XIIa inhibitors for HAE and other indications. Plasma kallikrein is a serine protease enzyme that is a key mediator of inflammation and edema.

Sector

Pharmaceuticals

Calendar

05/09/2024 - Bradykinin Symposium

More about the company

Income Statement Evolution

More financial data

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

11.79 USD

Average target price

29.8 USD

Spread / Average Target

+152.76%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Biopharmaceuticals

	1st Jan change	Capi.
KALVISTA PHARMACEUTICALS, INC.	-3.76%	50Cr
CSL LIMITED	+4.57%	9.77TCr
SAMSUNG BIOLOGICS CO.,LTD.	+5.66%	4.14TCr
BIOGEN INC.	-12.80%	3.29TCr
UCB	+80.99%	2.93TCr
BIOMARIN PHARMACEUTICAL INC.	-15.53%	1.55TCr
INCYTE CORPORATION	-8.70%	1.29TCr
BEIJING WANTAI BIOLOGICAL PHARMACY ENTERPRISE CO., LTD.	-12.22%	1.15TCr
ALTEOGEN INC.	+183.25%	1.07TCr
CHONGQING ZHIFEI BIOLOGICAL PRODUCTS CO., LTD.	-55.41%	897.35Cr

Biopharmaceuticals